FendlerLab

What FendlerLab does

FendlerLab (also known as FENDLERlab, ZBiMT, and the Department of Biostatistics and Translational Medicine) is an academic research group within the Medical University of Łódź (Uniwersytet Medyczny w Łodzi) in Poland, established as a department in 2019 and led by Prof. Wojciech Fendler. The group conducts translational medicine research bridging basic biological science and clinical applications, with primary focuses on oncology (urothelial carcinoma, glioblastoma, breast cancer, DNA damage repair pathways including 53BP1 and BRCA1/2 and cGAS-STING), diabetes (continuous glucose monitoring data analysis, glucose disposal rate prediction), and clinical biostatistics. Its technology stack centers on multi-omics analysis, bioinformatics, spatial transcriptomics, ATAC-seq, biomarker discovery, machine learning for medical data, and mathematical modeling of tumor evolution; it also develops research-grade analytical tools such as GlyCulator 3.0 (a CGM data analysis tool) and operates the ENDOVO research project on photoacoustic imaging for radiation therapy response assessment.

The lab serves the academic and clinical research community rather than commercial customers. Its distribution is almost entirely through peer-reviewed open-access publications in top-tier journals (Nature Communications, Cancer Research, Blood, Leukemia, Lancet Haematology, Cell Reports, Advanced Science, Molecular Oncology, PLOS Medicine, Diabetologia) and through international scientific conferences. It maintains a broad collaboration network spanning Harvard Medical School, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Moffitt Cancer Center, Icahn School of Medicine at Mount Sinai, San Diego State University, Hospital del Mar/IMIM, the National and Kapodistrian University of Athens, and the Oklahoma Medical Research Foundation.

Financially, FendlerLab is a non-commercial, government-funded academic unit. It does not sell products or services; its operations are sustained through competitive research grants from Polish and EU funding bodies including the National Science Centre (NCN — OPUS, PRELUDIUM BIS), the Foundation for Polish Science (START scholarships), the Polish National Agency for Academic Exchange (NAWA), and the National Medical Research Agency (ABM). As such, conventional revenue, pricing, and customer metrics are not applicable, and the entity is not investable in the venture capital or buyout sense.

Name

FendlerLab

Legal name

Medical University of Łódź (Uniwersytet Medyczny w Łodzi)

Website

https://biostat.umed.pl

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

FendlerLab (FENDLERlab / ZBiMT) is an academic research group within the Medical University of Łódź, Poland, conducting translational medicine research in oncology, diabetes, DNA repair, biostatistics, and multi-omics, serving the academic and clinical research community through publications, tools (e.g., GlyCulator 3.0), and international collaborations.

Ownership category

akta.pro rank

Product category

Academic Research / Translational Medicine

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAIALAF

Translational Medicine & Biomarkers

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

• Translational medicine research
• Biostatistics and bioinformatics
• Biomarker discovery research
• Multi-omics data analysis
• Cancer genomics research

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels3 records

Core offering

FendlerLab is an academic research group within the Department of Biostatistics and Translational Medicine (ZBiMT) at the Medical University of Łódź, Poland. The group conducts translational medicine research bridging basic science and clinical applications, with focus areas in oncology, diabetes, and molecular diagnostics. It produces peer-reviewed publications, develops analytical tools (e.g., GlyCulator 3.0), and runs research projects such as ENDOVO on photoacoustic imaging for cancer therapy response assessment.

Product overview

FendlerLab is a research group within the Department of Biostatistics and Translational Medicine (ZBiMT) at the Medical University of Łódź. The group conducts academic research in biostatistics, translational medicine, oncology, diabetes, and related fields. Based on the available sources, no commercial products or services are offered — the group primarily produces peer-reviewed academic publications, conducts clinical research, and develops research tools. The group collaborates internationally with institutions such as Dana-Farber Cancer Institute, Harvard Medical School, and others.

Differentiator

Problem solved

Functional benefit

Brands

• ENDOVO: Research project focused on photoacoustic imaging for radiation therapy response assessment in cancer.

Products and services

• GlyCulator 3.0 A CGM data analysis tool developed by the Department of Biostatistics and Translational Medicine for analyzing continuous glucose monitoring data, supporting diabetes research and clinical interpretation.
• ENDOVO A research project focused on photoacoustic imaging for early radiation therapy response assessment in breast cancer, as evidenced in the Advanced Science publication.
• Translational Medicine Research Services Academic research services in biostatistics, bioinformatics, multi-omics analysis (spatial transcriptomics, ATAC-seq), biomarker discovery, DNA repair mechanism research, and systematic review and meta-analysis for translational medicine applications in oncology, diabetes, and molecular diagnostics.

Quantifiable outcome

• Publications in top-tier journals including Nature Communications, Cancer Research, Blood, Leukemia, Lancet Haematology, Cell Reports, and multiple other high-impact publications
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Nine partnerships are on record, tiered core and major.

• Dana-Farber Cancer InstitutecoreStrategic or Co-development Partner · 2 June 2026International research collaboration on urothelial carcinoma research; Dr. Konrad Stawiski conducted research at Dana-Farber; ongoing collaboration with Harvard Medical School affiliates for bladder cancer research
• Harvard Medical SchoolcoreStrategic or Co-development PartnerLong-standing collaboration with Prof. Dipanjan Chowdhury's team; co-authored publications in Nature journal family; Dr. Stawiski received NAWA scholarship for research at Dana-Farber/Harvard
• Brigham and Women's HospitalcoreStrategic or Co-development PartnerCollaboration on advanced muscle-invasive urothelial carcinoma research as part of international research team
• Hospital del Mar/IMIMmajorStrategic or Co-development PartnerInternational collaboration partner in urothelial carcinoma study involving three independent patient cohorts
• National and Kapodistrian University of AthensmajorStrategic or Co-development PartnerInternational academic collaboration in cancer research studies
• Moffitt Cancer CentercoreStrategic or Co-development PartnerCollaboration on glioblastoma research; international team developing mathematical models for tumor evolution analysis
• Icahn School of Medicine at Mount SinaicoreStrategic or Co-development PartnerInternational collaboration on glioblastoma clonal evolution research as part of multi-institutional team
• San Diego State UniversitymajorStrategic or Co-development PartnerAcademic research collaboration on mathematical modeling of tumor microenvironment and glioblastoma evolution
• Oklahoma Medical Research FoundationmajorStrategic or Co-development PartnerStudent Paulina Urynowicz selected for BioLab Program research internship under Prof. Umesh S. Deshmukh; research on autoimmunity and biomarkers

Recent moves6 records

Expansion highlights5 records

Others

• Bio-Techne: Life science reagents, instruments, and analytical tools supplier used by translational researchers — adjacent enabling supplier to FENDLERlab's multi-omics and spatial analytics workflows.

Direct peers

• Tempus Labs: Precision medicine platform combining multi-omics, AI, and clinical data to support oncology and disease research — directly comparable to FENDLERlab's translational medicine and multi-omics biomarker pipeline.
• Flatiron Health: Oncology-focused real-world data and clinical research platform built on registry-scale analyses — directly comparable to FENDLERlab's registry meta-analyses and tumor microenvironment studies.
• NanoString Technologies: Spatial transcriptomics and multi-omics tools widely used in translational research — closely aligned with FENDLERlab's spatial transcriptomics and biomarker discovery work.
• Owkin: Federated learning and AI applied to oncology and translational research, partnering with academic medical centers — comparable end-customer mix and ML-for-medical-data approach to FENDLERlab.
• SOPHiA Genetics: AI-driven genomic and multimodal data analytics company serving clinical research, hospitals, and biopharma — comparable to FENDLERlab's biomarker discovery and biostatistics applied to clinical genomics.

Broad incumbents

• Schrödinger: Computational biology and molecular simulation platform serving pharma and biotech R&D — comparable computational/methodological research posture to FENDLERlab's mathematical tumor evolution modeling.
• Q² Solutions: Clinical research services provider with strong biostatistics and bioanalytical offerings — overlaps with FENDLERlab's biostatistics and translational clinical study design work.
• Foundation Medicine (Roche): Molecular profiling and molecular tumor board services for oncology — adjacent to FENDLERlab's cancer genomics, tumor microenvironment, and translational biomarker activities.

Emerging players

• Fabric Genomics: Clinical interpretation platform for next-generation sequencing data in hereditary and oncology applications — overlaps with FENDLERlab's clinical interpretation of molecular tumor and biomarker data.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/zbimt

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FendlerLab